TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06840496: To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Sponsor: Biomed Industries, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 210 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,111,504

Rescue Site Savings

+$2,074,336

Unlock Full NCT06840496 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06840496 Rescue Dossier →